Why Genmab’s epcoritamab quietly changes lymphoma treatment expectations

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 13:34. Details in the imprint.

Epcoritamab is the kind of drug name that never shows up on a billboard, yet for people with stubborn B-cell lymphomas it can feel like a small, quiet promise in a syringe. The Genmab antibody is given under the skin, not as an hours-long drip, and that simple difference changes how treatment days feel. Patients see a nurse, feel the sting of a subcutaneous injection, wait for monitoring – and then, often, go home.

What epcoritamab is designed to do

At its core, epcoritamab is a bispecific antibody, built to grab a cancer cell with one hand and a T cell of the immune system with the other. That bridge pulls the body’s own killer cells right up to malignant B cells in certain lymphomas. The idea is brutally simple and elegant at once.

The product is co-developed and co-commercialized with AbbVie, which brings big-pharma scale to Genmab’s antibody engineering focus. In practice, that means Genmab does not carry the entire commercialization burden alone, but shares development costs, milestones, and future revenues with its US partner.

How treatment feels for patients

Unlike many older lymphoma regimens that tie patients to an infusion chair for half a day, epcoritamab is given as a subcutaneous shot, usually into the abdomen or thigh. The nurse prepares a small syringe, disinfects the skin, injects slowly, and then watches closely for reactions in the first cycles.

Those first weeks are intense. Because the drug activates T cells, doctors worry about cytokine release syndrome, fevers, chills, and blood pressure swings. Patients are often monitored on site or even admitted for early doses, and they learn quickly to report headaches, confusion, or breathing changes immediately.

Where the clinical data impress – and where not

In relapsed or refractory large B-cell lymphoma, response rates with epcoritamab in clinical studies have been striking for a patient group that has already burned through several therapies. Many patients see their tumors shrink on scans, some reach complete remission, and a portion stay there for months.

But the picture is not cleanly rosy. Not every patient responds, and some who initially do well see their disease return. The safety profile, while manageable, is far from trivial: serious cytokine release, infections, and neurologic events have all been seen, requiring careful dose escalation and hospital infrastructure.

Dosing, logistics, and everyday impact

The dosing schedule typically starts with an intensive phase of weekly injections, then stretches out as patients remain on treatment, so the calendar slowly loosens its grip. For people in remote regions, though, even weekly hospital visits for a subcutaneous drug can still be a logistical burden.

Because epcoritamab is a biologic, there is no friendly pill bottle to take home and no pharmacy generic on the horizon. Cold chain storage, trained oncology staff, and reimbursement approvals shape whether a patient actually feels the benefits promised on paper.

Pricing, access, and regional realities

As a modern antibody co-launched by a mid-cap biotech and a global pharma, epcoritamab sits in the high-price segment typical for oncology biologics. Exact list prices vary by region and payer, and confidential rebates are common in Europe and the US.

For German patients, access usually runs through specialized hematology-oncology centers that can handle the monitoring requirements. In other European markets and the US, national reimbursement decisions, private insurers, and hospital budgets decide whether epcoritamab is available beyond clinical trials.

What epcoritamab means for Genmab’s story

For Genmab A/S, epcoritamab is more than another line in a pipeline slide; it is proof that the company’s antibody engineering platform can deliver commercial-stage, co-owned products. Every new market approval and label expansion feeds directly into the royalty and profit-sharing streams investors watch.

Shares of Genmab A/S (DK0010272202) trade in Europe, including on Xetra in euros, giving German investors direct access to the Danish antibody specialist without an ADR route.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | DK0010272202 | GENMAB | boerse | 69589850 | bgmi